Stockholms Sjukhem
Stockholm, 112 19, Sweden
NCT Number: NCT05027620
The purpose of this study is to test the feasibility of a novel motor-cognitive home training intervention using eHealth technology among people with Parkinson's Disease
Looking for future studies?
Notify Me50 year and older
All sexes
Interventional
Not applicable
Stockholm, 112 19, Sweden
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.
Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period.
Time frame: 10-week period.
Participants will rate their satisfaction with using a digital survey following each training session. An average value will be calculated. This will measure the feasibility outcome - Acceptability of the intervention.
Time frame: 10-week period.
Participants will rate the intensity of the intervention using the Borg Rating of perceived, Exertion Scale (6-20) following each training session. According to this scale, lower numbers signify lower levels of exertion, and higher numbers signify higher levels of exertion. The aim is that participants levels of exertion will lie in the middle range (12-17) This will measure the feasibility outcome - Practicality or Ability to carry out the intervention.
Time frame: 10-week period.
Participants will rate the difficulty of the dual-task exercises using a 0-10 scale (higher scores = higher degree of difficulty) following each exercise session and scores will be averaged over the study period following. This will measure the feasibility outcome - Suitability of the intervention.
Time frame: 10-week period.
Total time logged in to the digital training app will be derived from system and expressed as a percentage of total recommended intervention time. This will measure the feasibility outcome - Demand of the intervention'.
Time frame: 10 week period
Participants will report all adverse events such as falls or other injuries acquired during the training session, during a once weekly telephone interview. This will measure the feasibility outcome Safety.
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
Measured by the ActiGraph accelerometer model GT3X+ (ActiGraph, Pensacola, FL, US) worn on the hip for seven consecutive days
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
10 meter walk test at self-selected and fast speeds respectively
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
Assessed during the 2 minute walk test (2MWT) in single and dual task conditions
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
Walk-12 G Questionnaire
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
30 second chair stand test
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
Mini Balance Evaluation Systems Test (Mini-BESTest)
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
Activity-specific Balance Confidence (ABC) scale
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
The Parkinson's Disease Questionnaire -39 (PDQ-39)
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
Swedish Exercise Self-Efficacy Scale (S-ESES)
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
Attention and psychomotor processing speed will be assessed by the Trail making test (TMT) conditions 2 (letter Sequencing) and 4 (number-Letter Switching (set-shifting)) from Delis-Kaplan Executive Function System (D-KEFS). Results are presented as time in seconds.
Time frame: i) Baseline, pre-intervention. ii) Immediately after the intervention (10-week home training)
Verbal function, initiation & task-set switching will be assessed by the Verbal fluency (Letter Fluency, Category Fluency, and Category Switching) from Delis-Kaplan Executive Function System (D-KEFS). Raw scores are converted to scaled scores.
Stiftelsen Stockholms Sjukhem
Other
Continued Support for Physical Activity in Everyday Life With Parkinson's Disease Using eHealth Technology
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06556173
Basal Ganglia Diseases, Brain Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT02445651
Basal Ganglia Diseases, Brain Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06390163
Basal Ganglia Diseases, Brain Diseases
Ankara, Turkey (Türkiye)
View Trial DetailsNCT04202757
Basal Ganglia Diseases, Brain Diseases
Houston, Texas, United States
View Trial Details